Company Overview

Septerna, Inc. is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery powered by its proprietary Native Complex Platform^TM. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of its deep pipeline of oral small molecule product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Septerna was launched in 2022 by preeminent drug discovery company builders and scientific leaders in the biochemistry, structural biology, and pharmacology of GPCRs.